Holen Sie sich die Stockscreener-App
32.16
4.72%
1.45
Handel nachbörslich:
32.01
-0.15
-0.47%
Schlusskurs vom Vortag:
$30.71
Offen:
$31.12
24-Stunden-Volumen:
3.37M
Relative Volume:
1.31
Marktkapitalisierung:
$4.08B
Einnahmen:
$642.82M
Nettoeinkommen (Verlust:
$-43.54M
KGV:
-91.99
EPS:
-0.3496
Netto-Cashflow:
$130.12M
1W Leistung:
+26.07%
1M Leistung:
+43.38%
6M Leistung:
+79.97%
1J Leistung:
+253.02%
1-Tages-Spanne:
$29.91
$32.31
1-Wochen-Bereich:
$25.20
$32.31
52-Wochen-Spanne:
$8.945
$32.31
10 X Genomics Inc Stock (TXG) Company Profile
Firmenname
10 X Genomics Inc
Sektor
Branche
Telefon
(925) 401-7300
Adresse
6230 STONERIDGE MALL ROAD, PLEASANTON, CA
Compare TXG vs VEEV, BTSG, TEM, HQY, HNGE
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TXG
10 X Genomics Inc
|
32.16 | 3.90B | 642.82M | -43.54M | 130.12M | -0.3496 |
VEEV
Veeva Systems Inc
|
178.72 | 29.86B | 3.20B | 908.91M | 1.39B | 5.4168 |
BTSG
Brightspring Health Services Inc
|
60.88 | 11.51B | 13.65B | 169.86M | 412.12M | 1.0758 |
TEM
Tempus Ai Inc
|
47.51 | 8.91B | 1.36B | -302.91M | -219.93M | -1.7182 |
HQY
Healthequity Inc
|
85.21 | 7.39B | 1.31B | 215.20M | 408.32M | 2.4627 |
HNGE
Hinge Health Inc
|
58.66 | 4.53B | 646.34M | -512.40M | 202.76M | -6.6871 |
10 X Genomics Inc Stock (TXG) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-31 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2025-12-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-12-02 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-09-11 | Eingeleitet | Piper Sandler | Neutral |
| 2025-02-13 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-09-03 | Eingeleitet | Leerink Partners | Outperform |
| 2024-07-22 | Hochstufung | Jefferies | Hold → Buy |
| 2024-07-18 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-07-10 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2024-06-27 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2024-06-25 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-06-03 | Fortgesetzt | Jefferies | Hold |
| 2024-05-01 | Herabstufung | TD Cowen | Buy → Hold |
| 2023-12-14 | Eingeleitet | Guggenheim | Buy |
| 2023-12-13 | Eingeleitet | Wolfe Research | Outperform |
| 2023-12-12 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2023-07-05 | Fortgesetzt | JP Morgan | Overweight |
| 2023-05-10 | Eingeleitet | Barclays | Overweight |
| 2023-03-31 | Eingeleitet | Stephens | Overweight |
| 2023-02-02 | Eingeleitet | UBS | Neutral |
| 2022-12-14 | Eingeleitet | Deutsche Bank | Buy |
| 2022-08-18 | Herabstufung | Goldman | Neutral → Sell |
| 2022-07-25 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-07-15 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-07-15 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-09-14 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-03-15 | Eingeleitet | William Blair | Outperform |
| 2020-12-02 | Eingeleitet | Goldman | Neutral |
| 2020-09-09 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-07-10 | Eingeleitet | Stifel | Buy |
| 2020-03-05 | Eingeleitet | Guggenheim | Buy |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2019-10-07 | Eingeleitet | BofA/Merrill | Buy |
| 2019-10-07 | Eingeleitet | Cowen | Outperform |
| 2019-10-07 | Eingeleitet | JP Morgan | Overweight |
| 2019-09-24 | Eingeleitet | Evercore ISI | Outperform |
Alle ansehen
10 X Genomics Inc Aktie (TXG) Neueste Nachrichten
Deutsche Bank Adjusts Price Target on 10x Genomics to $30 From $23, Maintains Hold Rating - marketscreener.com
10x Genomics CEO Sells Nearly 30,000 Shares. Here's What That Means for Investors. - Yahoo Finance
10X Genomics Hits Day High with 9.72% Surge, Outperforming Market - Markets Mojo
10x Genomics stock hits 52-week high at 26.56 USD By Investing.com - Investing.com Nigeria
10x Genomics stock hits 52-week high at 26.56 USD - Investing.com
10x genomics president Hindson sells $283,399 in company stock By Investing.com - Investing.com Australia
10x genomics president Hindson sells $283,399 in company stock - Investing.com UK
10x genomics CEO Serge Saxonov sells $709,057 in shares - Investing.com
10x Genomics CFO Adam Taich sells $369,017 in stock By Investing.com - Investing.com South Africa
10x Genomics CFO Adam Taich sells $369,017 in stock - Investing.com
10x Genomics (NASDAQ: TXG) CEO sells 28,893 shares under 10b5-1 tax-related plan - Stock Titan
10x Genomics (TXG) officer sells 11,595 shares to cover RSU taxes - Stock Titan
10x Genomics (TXG) CFO sells 15,098 shares to cover RSU taxes - Stock Titan
TXG Stock Chart | 10X GENOMICS INC-CLASS A (NASDAQ:TXG) - ChartMill
TXG Genomics (NASDAQ: TXG) Serge Saxonov lists recent Class A sales in Form 144 - Stock Titan
Citigroup downgrades 10x Genomics (TXG) - MSN
10x Genomics Inc Class A Trade Ideas — LS:A2PPQJ - TradingView
Serge Saxonov (TXG) reports multiple 2026 sales and a 35,270-share RSU grant - Stock Titan
TXG (NASDAQ) Form 144: RSU grant 26,276 shares; insider sold 7,826 - Stock Titan
Adam Taich to sell 32,648 TXG shares (TXG) - Stock Titan
TXG News | 10X GENOMICS INC-CLASS A (NASDAQ:TXG) - ChartMill
10x Genomics, Inc.Common Stock (NQ: TXG - FinancialContent
10X Genomics’ SWOT analysis: stock faces profitability test - Investing.com
The 5 Most Interesting Analyst Questions From 10x Genomics’s Q1 Earnings Call - Yahoo Finance
10x Genomics Q1 earnings call highlights - MSN
The Bull Case For 10x Genomics (TXG) Could Change Following Mixed Q1 Results And Reaffirmed Guidance - Sahm
Precision Trading with 10x Genomics Inc. (TXG) Risk Zones - Stock Traders Daily
TXG Technical Analysis & Stock Price Forecast - Intellectia AI
10x Genomics seen as key player in AI-driven biological data buildout - MSN
Analysts Are Updating Their 10x Genomics, Inc. (NASDAQ:TXG) Estimates After Its First-Quarter Results - Sahm
QUADRANT CAPITAL GROUP LLC's 10x Genomics Inc(TXG) Holding History - GuruFocus
Why 10x Genomics (TXG) Stock Is Down Today - Yahoo Finance
10x Genomics Inc (TXG) Stock Price, Trades & News - GuruFocus
10x Genomics settles suit with rival and targets DNA sequencing startup - Life Sciences Intellectual Property Review
This $4 Million Bet Shows Growing Confidence in 10x Genomics as Stock Surges 116% - Yahoo Finance
This $4 Million Bet Shows Growing Confidence in 10x Genomics as Stock Surges 116% - The Motley Fool
10x Genomics (NASDAQ:TXG) Price Target Raised to $20.00 at JPMorgan Chase & Co. - MarketBeat
Morgan Stanley Lifts Price Target on 10x Genomics to $22 From $20, Keeps Equalweight Rating - Moomoo
10x Gene-Expression Patent Trial Nixed as Curio Deal Nears (1) - Bloomberg Law News
10x Genomics Q1 Earnings Call Highlights - sharewise.com
MSN Money - MSN
10x, Curio Settle Genomics Patent Suit Before Trial - Law360
Finanzdaten der 10 X Genomics Inc-Aktie (TXG)
Umsatz
Nettogewinn
Free Cashflow
ENV
10 X Genomics Inc-Aktie (TXG) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Saxonov Serge | Chief Executive Officer |
May 26 '26 |
Sale |
24.71 |
10,718 |
264,833 |
1,138,380 |
| Hindson Benjamin J. | See Remarks |
May 22 '26 |
Sale |
24.44 |
11,595 |
283,399 |
502,000 |
| Taich Adam | Chief Financial Officer |
May 22 '26 |
Sale |
24.44 |
15,098 |
369,018 |
379,898 |
2.19%
0.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):